From artificial intelligence to pluripotent stem cells, this year saw the publication of a bevy of intriguing new methods, as well as tweaks to existing protocols.
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool?